Bifunctional BTK Degrading Compounds Via Ubiquitin Proteasome Pathway

Sat, 18 Apr 2026 03:29:10 +0000
Intellectual Property

The European Patent Office published patent EP3924350A1, granted to Nurix Therapeutics, Inc., covering bifunctional compounds for degrading BTK via the ubiquitin proteasome pathway. The patent application includes six IPC classifications spanning pharmaceutical compositions and therapeutic methods. Protection extends across 31 designated European states including major markets.